MedPath

A Randomised Controlled Trial of Omega 3 Fatty Acids in the Management of Antipsychotic-Induced Movement Disorders

Phase 4
Conditions
Mental and Behavioural Disorders
Registration Number
PACTR202108856656364
Lead Sponsor
Dr Sammy Ohene
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
120
Inclusion Criteria

A confirmed diagnosis of antipsychotic-induced movement disorder
Participants aged between 18 and 60years.
On a stable dose of antipsychotic medication within 3 months prior to study
Patients in the control arm should not have initiated anti-cholinergic therapy
Patients should demonstrate a commitment not to initiate or modify interventions during the period of the study.

Exclusion Criteria

Patients whose psychiatric disorder was not stable;
Patients with a significant organic neurological disorder other than the mental disorder
Treatment with omega-3 therapy 3months prior to study
Patients who were pregnant or breastfeeding.
Patients with a diagnosis of substance dependence (DSM-IV),
Patients with a known allergy to omega 3 fish oil or sea foods

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath